Propionyl-L-Carnitine
Phase 3Small molecule
Propionyl-L-Carnitine is one of 80 small molecule programs targeting Peripheral Arterial Disease. It is currently in Phase 3.
2
Indications
5
Total Trials
0
Active Trials
79
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
460 competitors in Ulcerative Colitis
#DrugCompanyPhaseTrials
1Omvoh
Eli LillyPhase 3
Mounjaro
Eli LillyPhase 3
Icotyde
Johnson & JohnsonPhase 3
Purinethol
SStason
Phase 3
CP-690,550
PfizerPhase 3
SHR0302
RReistone Biopharma Company Limited
Phase 3
PTM SEMA
GileadPhase 3
Propionyl-L-Carnitine
LLee's Pharmaceutical Limited
Phase 3
Simponi
Johnson & JohnsonPreclinical
CT-P13 SC (infliximab)
CCelltrion
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Ulcerative Colitis3 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Propionyl-L-Carnitine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- LLee's Pharmaceutical Limited